Toward the Commercialization of a Proteolytically Resistant APPI Variant for Inhibiting Metastasis in Prostate and Pancreatic Cancer

Project description

Novel inhibitor for metastatic prostate and pancreatic cancer

Fields of science

• natural sciences › biological sciences › biochemistry › biomolecules › proteins
• medical and health sciences › clinical medicine › cancer › prostate cancer
• medical and health sciences › clinical medicine › cancer › pancreatic cancer

Programme(s)

• H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)

Topic(s)

• ERC-2019-POC - ERC Proof of Concept Grant

Call for proposal

ERC-2019-PoC
See other projects for this call

Funding Scheme

ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot

Host institution

BEN-GURION UNIVERSITY OF THE NEGEV

Address

.
84105 Beer Sheva
Israel

Activity type

Higher or Secondary Education Establishments

EU contribution

€ 150 000

Beneficiaries (1)

BEN-GURION UNIVERSITY OF THE NEGEV

Israel

EU contribution

€ 150 000

Address

.
84105 Beer Sheva

Activity type

Higher or Secondary Education Establishments